FMT in 2026: What the Evidence Actually Says — From C. difficile Through Ulcerative Colitis to the Gut-Brain Frontier
- Jeffrey Tu
- 2 days ago
- 8 min read
Faecal microbiota transplant has, in the space of fifteen years, travelled from the margins of gastroenterology to one of the most intensively studied therapies in medicine. It is also one of the most misunderstood. In the popular imagination it is either a miracle cure for every modern malaise or a fringe experiment best left to other people; in specialist practice it is neither. FMT in 2026 is a precise, evidence-graded intervention with clearly established indications, a growing list of emerging ones, and a fast-moving research frontier that now extends all the way into psychiatry. This is the expert guide to where the evidence actually sits — what we know, what we are still learning, and what we at Shore Gastroenterology now offer as a multi-modal, multi-donor protocol that reflects the way the science has landed.
How FMT Actually Works — Ecosystem, Not Organism
FMT is not a single-organism probiotic scaled up. It is the transfer of an entire, functioning microbial ecosystem — thousands of bacterial species, archaea, fungi, bacteriophages, and the metabolic products they produce — from a rigorously screened healthy donor into the gut of a recipient whose own ecosystem has become dysbiotic, impoverished, or actively hostile. The graft brings with it not just taxonomic diversity but functional redundancy: the capacity to ferment fibre, generate short-chain fatty acids, regulate bile acids, produce neurotransmitter precursors, and crowd out pathogens. The therapeutic question is therefore never whether a single bacterium will treat a disease, but whether re-establishing a healthy ecosystem will allow the host's own biology to recover. That distinction — ecosystem versus organism — is why FMT succeeds where targeted single-strain probiotics have so consistently disappointed, and it is the conceptual foundation on which every protocol in this article rests.
The Gold Standard — Recurrent Clostridioides difficile
The anchor indication for FMT is recurrent C. difficile infection, and here the evidence is unambiguous. Across multiple randomised controlled trials and large real-world registries, a single FMT cures between 85 and 92 per cent of patients who have failed two or more rounds of conventional antibiotic therapy. By comparison, vancomycin taper achieves durable cure in fewer than a third of the same population. The mechanism is beautifully simple: C. difficile exploits the ecological vacuum left by broad-spectrum antibiotics, and FMT fills that vacuum faster than any other intervention we have. The FDA approvals of the first two stool-derived biotherapeutics — Rebyota and Vowst — formalised what the field already knew: for recurrent CDI, FMT is no longer alternative medicine, it is standard of care. In Australia and most developed systems it is now the preferred option after a second recurrence, and in selected severe or fulminant cases it is moved earlier still. The remaining debate is not whether FMT works in CDI — that is settled — but how to optimise it: single versus repeat dosing, fresh versus frozen preparations, route of delivery, and how much of the cure rate can be pushed beyond 90 per cent in the hardest cases.
Ulcerative Colitis — The Antibiotic-FMT Combination Era
Ulcerative colitis is the condition that has taught the field how to use FMT in chronic disease, and the story is one of careful protocol refinement rather than raw efficacy. The landmark FOCUS trial (Paramsothy and colleagues, 2017, The Lancet) showed that intensive FMT — roughly forty infusions over eight weeks, using pooled multi-donor stool — produced steroid-free clinical remission with endoscopic response in 27 per cent of patients, compared with 8 per cent on placebo. The Moayyedi and Rossen trials found broadly compatible numbers. These are not the headline-grabbing cure rates of CDI, but in a chronic relapsing autoimmune disease where every new biologic achieves remission rates in the 20 to 40 per cent range, they are clinically meaningful. The decade since has focused on two refinements. The first is antibiotic pre-conditioning: a short course of antibiotics such as vancomycin, metronidazole, or amoxicillin in the week before the graft appears to open ecological niches and markedly improve engraftment, with several trials now showing remission rates approaching 40 per cent when this protocol is used. The second is intensification: more frequent dosing during the induction phase, multi-donor pooling to maximise diversity, and combined delivery routes to ensure colonisation of both the proximal and distal colon. In 2026, UC-directed FMT is not a first-line therapy, but it is a credible option for patients who have failed or wish to defer biologics, and an increasingly considered adjunct for those with partial biologic response.
IBS — The Modest-but-Real Signal, and Why Donor Matters
In IBS, the evidence is messier, smaller, and more donor-dependent. Early trials produced conflicting results: Halkjaer and colleagues in 2018 found no benefit, while El-Salhy and colleagues in 2020, using carefully selected super-donor stool, reported significant and durable symptom improvement in 65 to 75 per cent of recipients. The difference between those trials was not methodology but biology — the donor microbiome matters more in IBS than in perhaps any other indication, because the disease is driven not by a single missing function but by a constellation of small dysbiotic shifts. In the subsequent years the signal has consolidated: FMT in IBS works best in diarrhoea-predominant disease, with well-characterised donors, in patients who have already exhausted the dietary and antimicrobial steps of the IBS treatment ladder. Remission is rarely durable after a single infusion, and most modern protocols incorporate a capsule-based maintenance phase to extend the benefit. It is not a first-line therapy, it is not appropriate for every IBS phenotype, and it is certainly not a substitute for proper FODMAP, SIBO, and gut-brain work. But for the refractory IBS patient who has done everything else, it is a genuine option.
The Frontier — FMT and the Mind
The most striking development of the last five years has been the movement of FMT into psychiatric research. The theoretical basis is the gut-brain axis, which we explore in detail in The Gut-Brain Axis Explained, and the empirical basis is a rapidly growing series of studies connecting microbial composition to mood, cognition, and behaviour. Three areas are furthest advanced. In depression, several small randomised and open-label trials have shown meaningful reductions in depressive symptoms following FMT, particularly in patients with comorbid functional gut disease, and larger RCTs are now under way. In bipolar disorder, the case for FMT is newer but accelerating: case series, small trials, and emerging RCT data point to improvements in mood stability, sleep, and relapse rates in patients with treatment-resistant disease, and I have written about this in more detail in our companion piece, FMT for Bipolar Disorder. In autism spectrum disorder, the Microbiota Transfer Therapy programme originally published by Kang and colleagues reported durable improvements in gastrointestinal symptoms and in core autism-related behaviours over two-year follow-up, and the work extending that protocol is among the most closely watched in the field. Outside these three, there are early but credible signals in anxiety, chronic fatigue, long COVID, and Parkinson's disease. It is important to be clear about what this evidence is and is not: none of these are yet standard-of-care indications, the effect sizes are variable, and the field is still untangling which patients, which donors, and which protocols produce durable benefit. But the direction of travel is unmistakable, and the idea that the gut microbiome is a legitimate therapeutic target in neuropsychiatric disease is no longer controversial.
The question in 2026 is no longer whether FMT works. It is how to deliver the right ecosystem, to the right patient, at the right time — and that is a protocol design question, not a belief question.
The Shore Multi-Modal, Multi-Donor Protocol
When the evidence across CDI, UC, IBS, and the neuropsychiatric frontier is read together, three design principles emerge — and these principles shape the protocol I offer at Shore Gastroenterology. The first is mixed delivery. The colon is not a single compartment; it is a continuum of ecological niches from caecum to rectum, each with its own bacterial density, oxygen tension, and transit time. No single delivery route reliably colonises the whole colon: oral capsules seed the proximal small bowel and right colon, transcolonic infusion at colonoscopy places a concentrated graft deep in the caecum with the highest engraftment probability, and retention enemas colonise the distal colon where much of ulcerative colitis and IBS pathology lives and where standard capsules do not reliably reach. My protocol uses all three routes in combination, staged across the induction period, to ensure coverage from the ileocaecal valve to the rectum. There is a growing body of comparative evidence that multi-modal delivery outperforms any single route in both UC and refractory CDI, and the early neuropsychiatric data suggests the same is likely to be true there.
The second principle is multi-donor pooling. A single donor, however healthy, cannot supply the full spectrum of microbial diversity that a depleted recipient ecosystem needs to rebuild. Multi-donor pooled preparations — in which screened stool from several rigorously vetted donors is combined — consistently increase the taxonomic and functional diversity of the graft and, in the FOCUS and subsequent UC trials, were associated with higher remission rates than single-donor products. The biological argument is straightforward: a pooled graft offers the recipient a richer menu of ecological niches to draw from, increasing the probability that the specific strains that patient needs are actually present in the preparation. The statistical argument reinforces it: combining donors cancels out idiosyncratic donor weaknesses and captures complementary strengths. My protocol uses a pooled multi-donor preparation, with donors screened to contemporary international standards for pathogens, antibiotic-resistant organisms, metabolic markers, and mental health history.
The third principle is attention to pre-conditioning and maintenance. A short, targeted course of antibiotics before the induction phase opens ecological niches and substantially improves engraftment; a structured capsule-based maintenance phase after induction helps sustain the graft through the weeks in which it is consolidating. In refractory cases, booster infusions at three and six months are increasingly part of the standard picture, and the evidence base for this staged approach is growing quickly. No protocol is a panacea, and no FMT is a substitute for doing the foundational work — dietary, antimicrobial, psychological, and medical — first. But for the right patient, a properly designed, multi-modal, multi-donor protocol is the most evidence-aligned way to deliver this therapy in 2026.
Donor Screening and Safety
The safety of modern FMT rests on the rigour of donor screening, and this is where the field has matured most dramatically in the last decade. Contemporary donors are screened across more than thirty pathogens and markers: stool testing for C. difficile, enteric pathogens, ova, cysts, parasites, multi-drug resistant organisms, Helicobacter antigen, and norovirus; blood testing for HIV, hepatitis A/B/C/E, syphilis, HTLV, EBV, CMV, and emerging pathogens; and extensive health questionnaires covering metabolic, autoimmune, allergic, and mental health history. Adverse events in properly screened programmes are uncommon and usually mild — transient bloating, low-grade fever, and self-limited changes in bowel habit in the first days after infusion. Serious adverse events are rare and, in the overwhelming majority of reported cases, traceable to inadequate donor screening. The takeaway is that FMT is safe when it is delivered inside a programme that takes donor selection seriously, and that choosing the programme matters as much as choosing the indication.
Who Is a Candidate
In 2026, FMT is clearly indicated for recurrent or refractory C. difficile and is a considered option for selected patients with ulcerative colitis, refractory diarrhoea-predominant IBS, and — increasingly, within research frameworks — treatment-resistant depression, bipolar disorder, and autism spectrum disorder. It is not a general-purpose restorative therapy, it is not a replacement for dietary and medical optimisation, and it is not an appropriate first step for most patients. It is, however, the right step for a carefully selected subset who have done the foundational work and still need more. If your condition fits one of the indications above, or if you have followed the usual ladder and want to know whether FMT is a reasonable next step in your case, a specialist review is the place to start. The questions worth asking are: what is the evidence in my specific condition, what would the protocol look like, what is the realistic benefit I could expect, and what is the follow-up plan to maximise engraftment and durability? At Shore Gastroenterology this is a conversation we have often, and it is the kind of precision-aligned, evidence-led care that defines the service.
Closing
FMT in 2026 is not a miracle, and it is not a fad. It is a carefully studied, increasingly precise, ecosystem-level therapy with a clear gold-standard indication, a strong and growing set of chronic-disease indications, and a research frontier that now reaches into neuropsychiatry. Used well, in the right patient, inside a rigorous programme, it is one of the most powerful interventions in modern gastroenterology. Used badly, it is a disappointment. The difference is the depth of the assessment, the quality of the programme, and the honesty with which the evidence is conveyed. That is what this article has tried to do, and it is what I hope to continue offering in the clinic.
Comments